Beacon Pharmaceuticals is a large pharmaceutical company invested by the European consortium and the famous European consultant company as a technical team. It is the only pharmaceutical company in South Asia to implement the EU technical specification. The company is a large enterprise listed on the two major securities trading boards in Dhaka and Chittagong, Bangladesh. The European Pharmacopoeia and the standard of the American Pharmacopoeia.
According to the WTO of the world trade organization, Bangladesh, as an underdeveloped member country, can obtain immunity from patent protection of pharmaceutical products and clinical data in developed countries, and produce any new generic drugs of the world under the strict supervision of the Bangladesh government.
Beacon Pharmaceuticals has produced many of the world's first generic drugs, such as the three generation of the new hepatitis C drug, which is suitable for all genotypes, and is suitable for the new drug of chronic hepatitis B, such as tenofovir Ella Phenolamine TAF, and so on. In addition, Beacon Pharmaceuticals also produced a number of the world's first antitumor drugs, such as Ohiti Ni, kazoinib, suoninib, regeni, afitinib, and so on. In the future, Beacon Pharmaceuticals will also launch more than 30 world's first generic drugs each year.
In order to expand the market of mainland China and Hong Kong, Macao, Taiwan and Taiwan, we are looking for good communication and human resource integration, and Chinese partners with cooperation resources of hospitals and doctors to join us, to jointly expand the medical market in mainland China and Hong Kong, Macao and Taiwan, for Huan Youyi, hepatitis C and various types of cancer. Chinese patients, such as major diseases, offer affordable, well served medical tourism or telemedicine services to benefit the vast number of Chinese patients.
The main tasks of the partners are:
1. Legally registered medical tourism service enterprises can conduct telemedicine or medical tourism consultation, organization or consultancy services in accordance with the law.
2, according to the development plan of the company in the Chinese market, integrate the medical resources under the line, responsible for the company's medical channel business cooperation.
3, we are responsible for opening up the cooperation resources that benefit BHC in China, evaluating the cooperation of resources, formulating cooperation mechanisms and promoting cooperation.
4. Responsible for planning cooperative projects in all parts of China and maintaining business partnership.
